Last reviewed · How we verify
Oral contraceptives continuous
Oral contraceptives continuous, marketed by the University of Athens, holds a position in the contraceptive market with a key composition patent expiring in 2028. The drug's continuous dosing mechanism offers a distinct competitive advantage. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Oral contraceptives continuous |
|---|---|
| Also known as | Yasmin |
| Sponsor | University of Athens |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Polycystic Ovary Syndrome in Type 1 Diabetes
- Effects of Progressive Relaxation Exercises and Planned Training After Cesarean Section on Pain, Anxiety and Comfort (NA)
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (PHASE1)
- Role of Estrogen on Skeletal Outcomes in FHA (PHASE2)
- Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive (PHASE2)
- Continuous Versus Cyclical OCP Use in PCOS (PHASE4)
- Estrogen and Microvascular Function
- Kuwa Free! - Live Free! (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral contraceptives continuous CI brief — competitive landscape report
- Oral contraceptives continuous updates RSS · CI watch RSS
- University of Athens portfolio CI